Zhang et al. [100] reported that AS-IV had a beneficial effect in reducing precancerous lesions of gastric carcinoma by inhibiting glycolysis through the regulation of the p53/miRNA-34a/LDHA and p53/TIGAR pathways. This evidence concerns the gene TP53 and gastric carcinoma.